Eliem Therapeutics Relocates Principal Executive Offices
Ticker: CLYM · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1768446
| Field | Detail |
|---|---|
| Company | Eliem Therapeutics, INC. (CLYM) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $110 million, $20 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, address-change
TL;DR
Eliem Therapeutics moved its HQ to Delaware.
AI Summary
Eliem Therapeutics, Inc. filed an 8-K on March 19, 2024, reporting an event on March 14, 2024. The filing indicates a change in the company's principal executive offices to Wilmington, Delaware, from its previous address in Redmond, Washington. This move is effective as of March 14, 2024.
Why It Matters
A change in principal executive offices can signal operational shifts or a strategic move to a new business environment, potentially impacting local operations and employee base.
Risk Assessment
Risk Level: low — This filing primarily concerns a change of address for the company's principal executive offices, which is a routine administrative event with no immediate financial or operational implications.
Key Players & Entities
- Eliem Therapeutics, Inc. (company) — Registrant
- Wilmington, Delaware (location) — New principal executive offices
- Redmond, WA (location) — Former principal executive offices
- March 14, 2024 (date) — Effective date of address change
- March 19, 2024 (date) — Filing date of the 8-K
FAQ
What is the new address for Eliem Therapeutics' principal executive offices?
The new address is 2801 Centerville Road, 1st Floor, PMB #117, Wilmington, DE 19808-1609.
When was the change of address effective?
The change of address was effective as of March 14, 2024.
What was the previous address of Eliem Therapeutics' principal executive offices?
The previous address was 23515 NE Novelty Hill Road, Suite B221 #125, Redmond, WA 98053.
What type of filing is this for Eliem Therapeutics?
This is a Form 8-K, a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Commission File Number for Eliem Therapeutics?
The Commission File Number is 001-40708.
Filing Stats: 1,482 words · 6 min read · ~5 pages · Grade level 16.5 · Accepted 2024-03-18 18:34:02
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ELYM The Nasdaq Stock Mar
- $110 million — io would value the Company initially at $110 million as of the closing of the Proposed Trans
- $20 million — hile Tango would initially be valued at $20 million; In connection with the closing of th
Filing Documents
- d784366d8k.htm (8-K) — 36KB
- d784366dex991.htm (EX-99.1) — 14KB
- 0001193125-24-070333.txt ( ) — 207KB
- elym-20240314.xsd (EX-101.SCH) — 3KB
- elym-20240314_def.xml (EX-101.DEF) — 13KB
- elym-20240314_lab.xml (EX-101.LAB) — 21KB
- elym-20240314_pre.xml (EX-101.PRE) — 14KB
- d784366d8k_htm.xml (XML) — 5KB
Forward-Looking Statements
Forward-Looking Statements
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Non-Binding Term Sheet 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Eliem Therapeutics, Inc. Date: March 18, 2024 By: /s/ Andrew Levin Andrew Levin, M.D., Ph.D. Executive Chairman of the Board of Directors